BBBalazs Banfai

Balazs Banfai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Balazs Banfai has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Manuel Tzouros

    Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland

    4 shared publications
  • Tom Dunkley

    Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland

    4 shared publications
  • Jitao David Zhang

    Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland

    3 shared publications
  • Sándor Kemény

    Department of Chemical and Environmental Process Engineering Budapest University of Technology and Economics Budapest Hungary

    3 shared publications
  • Christoph Patsch

    Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland

    2 shared publications
  • Iakov I. Davydov

    Computational Sciences Center of Excellence, Roche Innovation Center Basel, Basel, Switzerland

    2 shared publications

Latest Publications

  • designit: Blocking and Randomization for Experimental Design

    by Iakov I. Davydov, Juliane Siebourg-Polster, Guido Steiner, Jitao David Zhang, Balazs Banfai

  • Open Access

    Secreted retrovirus-like GAG-domain-containing protein PEG10 is regulated by UBE3A and is involved in Angelman syndrome pathophysiology

    by Nikhil J. Pandya, Congwei Wang, Veronica Costa, Paul Lopatta, Sonja Meier, F. Isabella Zampeta, A. Mattijs Punt, Edwin Mientjes, Philip Grossen, Tania Distler, et al.


  • Open Access

    MSstatsTMT: Statistical Detection of Differentially Abundant Proteins in Experiments with Isobaric Labeling and Multiple Mixtures

    by Ting Huang, Meena Choi, Manuel Tzouros, Sabrina Golling, Nikhil Janak Pandya, Balazs Banfai, Tom Dunkley, Olga Vitek


  • Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells

    by Filip Roudnicky, Jitao David Zhang, Bo Kyoung Kim, Nikhil J. Pandya, Yanjun Lan, Lisa Sach-Peltason, Heloise Ragelle, Pamela Strassburger, Sabine Gruener, Mirjana Lazendic, et al.

    Significance: Blood vessels in the central nervous system possess unique barrier properties that prevent infiltration of foreign substances and allow for precise delivery of ions, molecules, and immune cells into neural networks. Barrier breakdown is associated with a host of retinal and neurological disorders but few BRB/BBB-enhancing therapies have been developed. To identify novel barrier-inducing factors, we genetically engineered a transcriptional reporter cell line with CRISPR technology for compound library screening. Using this approach, we identified compounds, including a TGF-β receptor inhibitor, RepSox, which functions in vitro to increase barrier resistance in human primary and stem cell-derived endothelial cell lines. These data may inform future therapies for BRB/BBB disorders and retinal/neurological diseases.


  • Open Access

    Selection of Features with Consistent Profiles Improves Relative Protein Quantification in Mass Spectrometry Experiments

    by Tsung-Heng Tsai, Meena Choi, Balazs Banfai, Yansheng Liu, Brendan X. MacLean, Tom Dunkley, Olga Vitek


  • Top Cited Papers
    Open Access

    An Introduction to Machine Learning

    by Solveig Badillo, Balazs Banfai, Fabian Birzele, Iakov I. Davydov, Lucy Hutchinson, Tony Kam‐Thong, Juliane Siebourg‐Polster, Bernhard Steiert, Jitao David Zhang

    In the last few years, machine learning (ML) and artificial intelligence have seen a new wave of publicity fueled by the huge and ever‐increasing amount of data and computational power as well as the discovery of improved learning algorithms. However, the idea of a computer learning some abstract concept from data and applying them to yet unseen situations is not new and has been around at least since the 1950s. Many of these basic principles are very familiar to the pharmacometrics and clinical pharmacology community. In this paper, we want to introduce the foundational ideas of ML to this community such that readers obtain the essential tools they need to understand publications on the topic. Although we will not go into the very details and theoretical background, we aim to point readers to relevant literature and put applications of ML in molecular biology as well as the fields of pharmacometrics and clinical pharmacology into perspective.


  • Top Cited Papers
    Open Access

    Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers

    by Manaswini Sivaramakrishnan, Kathleen D. McCarthy, Sébastien Campagne, Sylwia Huber, Sonja Meier, Angélique Augustin, Tobias Heckel, Hélène Meistermann, Melanie N. Hug, Pascale Birrer, et al.

    Small molecule splicing modifiers have been previously described that target the general splicing machinery and thus have low specificity for individual genes. Several potent molecules correcting the splicing deficit of theSMN2(survival of motor neuron 2) gene have been identified and these molecules are moving towards a potential therapy for spinal muscular atrophy (SMA). Here by using a combination of RNA splicing, transcription, and protein chemistry techniques, we show that these molecules directly bind to two distinct sites of theSMN2pre-mRNA, thereby stabilizing a yet unidentified ribonucleoprotein (RNP) complex that is critical to the specificity of these small molecules forSMN2over other genes. In addition to the therapeutic potential of these molecules for treatment of SMA, our work has wide-ranging implications in understanding how small molecules can interact with specific quaternary RNA structures.


  • Open Access

    HtrA1 activation is driven by an allosteric mechanism of inter-monomer communication

    by Alvaro Cortes Cabrera, Esther Melo, Doris Roth, Andreas Topp, Frederic Delobel, Corinne Stucki, Chia-Yi Chen, Peter Jakob, Balazs Banfai, Tom Dunkley, et al.

    The human protease family HtrA is responsible for preventing protein misfolding and mislocalization, and a key player in several cellular processes. Among these, HtrA1 is implicated in several cancers, cerebrovascular disease and age-related macular degeneration. Currently, HtrA1 activation is not fully characterized and relevant for drug-targeting this protease. Our work provides a mechanistic step-by-step description of HtrA1 activation and regulation. We report that the HtrA1 trimer is regulated by an allosteric mechanism by which monomers relay the activation signal to each other, in a PDZ-domain independent fashion. Notably, we show that inhibitor binding is precluded if HtrA1 monomers cannot communicate with each other. Our study establishes how HtrA1 trimerization plays a fundamental role in proteolytic activity. Moreover, it offers a structural explanation for HtrA1-defective pathologies as well as mechanistic insights into the degradation of complex extracellular fibrils such as tubulin, amyloid beta and tau that belong to the repertoire of HtrA1.


  • Assessment of Preclinical Liver and Skeletal Muscle Biomarkers Following Clofibrate Administration in Wistar Rats

    by Pierre Maliver, Matthias Festag, Moritz Bennecke, Francois Christen, Balázs Bánfai, Barbara Lenz, Michael Winter

    Clofibrate is a known rodent hepatotoxicant classically associated with hepatocellular hypertrophy and increased serum activities of cellular alanine aminotransferase/aspartate aminotransferase (ALT/AST) in the absence of microscopic hepatocellular degeneration. At toxic dose, clofibrate induces liver and skeletal muscle injury. The objective of this study was to assess novel liver and skeletal muscle biomarkers following clofibrate administration in Wistar rats at different dose levels for 7 days. In addition to classical biomarkers, liver injury was assessed by cytokeratin 18 (CK18) cleaved form, high-mobility group box 1, arginase 1 (ARG1), microRNA 122 (miR-122), and glutamate dehydrogenase. Skeletal muscle injury was evaluated with fatty acid binding protein 3 (Fabp3) and myosin light chain 3 (Myl3). Clofibrate-induced hepatocellular hypertrophy and skeletal muscle degeneration (type I rich muscles) were noted microscopically. CK, Fabp3, and Myl3 elevations correlated to myofiber degeneration. Fabp3 and Myl3 outperformed CK for detection of myofiber degeneration of minimal severity. miR-122 and ARG1 results were significantly correlated and indicated the absence of liver toxicity at low doses of clofibrate, despite increased ALT/AST activities. Moreover, combining classical and novel biomarkers (Fabp3, Myl3, ARG1, and miR-122) can be considered a valuable strategy for differentiating increased transaminases due to liver toxicity from skeletal muscle toxicity.


  • Open Access

    Long noncoding RNAs are rarely translated in two human cell lines

    by Balázs Bánfai, Hui Jia, Jainab Khatun, Emily Wood, Brian Risk, William E. Gundling, Anshul Kundaje, Harsha P. Gunawardena, Yanbao Yu, Ling Xie, et al.

    Data from the Encyclopedia of DNA Elements (ENCODE) project show over 9640 human genome loci classified as long noncoding RNAs (lncRNAs), yet only ∼100 have been deeply characterized to determine their role in the cell. To measure the protein-coding output from these RNAs, we jointly analyzed two recent data sets produced in the ENCODE project: tandem mass spectrometry (MS/MS) data mapping expressed peptides to their encoding genomic loci, and RNA-seq data generated by ENCODE in long polyA+ and polyA− fractions in the cell lines K562 and GM12878. We used the machine-learning algorithm RuleFit3 to regress the peptide data against RNA expression data. The most important covariate for predicting translation was, surprisingly, the Cytosol polyA− fraction in both cell lines. LncRNAs are ∼13-fold less likely to produce detectable peptides than similar mRNAs, indicating that ∼92% of GENCODE v7 lncRNAs are not translated in these two ENCODE cell lines. Intersecting 9640 lncRNA loci with 79,333 peptides yielded 85 unique peptides matching 69 lncRNAs. Most cases were due to a coding transcript misannotated as lncRNA. Two exceptions were an unprocessed pseudogene and a bona fide lncRNA gene, both with open reading frames (ORFs) compromised by upstream stop codons. All potentially translatable lncRNA ORFs had only a single peptide match, indicating low protein abundance and/or false-positive peptide matches. We conclude that with very few exceptions, ribosomes are able to distinguish coding from noncoding transcripts and, hence, that ectopic translation and cryptic mRNAs are rare in the human lncRNAome.